Home > Cardiology > ACC 2019 > Acute and Stable Ischaemic Heart Disease > DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups

DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups

Conference
ACC 2019

Dapagliflozin is a first-in-class, oral, once-daily, selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2). The drug is indicated monotherapy as well as part of combination therapy to improve glycaemic control. Additional benefits include weight loss and blood pressure reduction, as an adjunct to diet and exercise in adults with type 2 diabetes mellitus (T2DM).

Dapagliflozin’s safety and efficacy was assessed in the DECLARE-TIMI 58 trial (n=17,160), which randomised patients 1:1 to either dapagliflozin 10 mg (n=8,582) or matching placebo (n=8,578). The mean age of the participants was 64, 37% was female, and the duration of follow-up was 4.2 years [1]. A distinguishing feature of DECLARE-TIMI 58 relative to other SGLT2i trials was the large population of patients without established cardiovascular disease (59.3%).

Dapagliflozin in peripheral artery disease patients

In 2018, dapagliflozin was shown to be superio...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on